4-hexylresorcinol inhibits NF-κB phosphorylation and has a synergistic effect with cisplatin in KB cells.
暂无分享,去创建一个
[1] Je-Yong Choi,et al. 4-Hexylresorcinol inhibits transglutaminase-2 activity and has synergistic effects along with cisplatin in KB cells. , 2011, Oncology reports.
[2] D. Schultz,et al. Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3-4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva. , 2011, Gynecologic oncology.
[3] K. Mehta,et al. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer. , 2010, Biochemical pharmacology.
[4] B. Aggarwal,et al. Inhibiting NF-κB activation by small molecules as a therapeutic strategy. , 2010, Biochimica et biophysica acta.
[5] Soo-Youl Kim,et al. I-kappaBalpha depletion by transglutaminase 2 and mu-calpain occurs in parallel with the ubiquitin-proteasome pathway. , 2010, Biochemical and biophysical research communications.
[6] Young-Wook Park,et al. Recapitulating orthotopic tumor model through establishment of a parotid gland tumor with lung metastasis using HeLa cell injection into nude mice. , 2010, Oncology reports.
[7] Jue Hu,et al. Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance. , 2009, Cancer treatment reviews.
[8] A. Verma,et al. Tissue transglutaminase-mediated chemoresistance in cancer cells. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[9] M. López-Caballero,et al. Spraying of 4-hexylresorcinol based formulations to prevent enzymatic browning in Norway lobsters (Nephrops norvegicus) during chilled storage , 2007 .
[10] V. Bours,et al. Can NF-kappaB be a target for novel and efficient anti-cancer agents? , 2006, Biochemical pharmacology.
[11] B. Aggarwal,et al. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. , 2006, Cancer research.
[12] N. Nam. Naturally occurring NF-kappaB inhibitors. , 2006, Mini reviews in medicinal chemistry.
[13] S. Radhakrishnan,et al. Pro-apoptotic role of NF-kappaB: implications for cancer therapy. , 2006, Biochimica et biophysica acta.
[14] J. Gossage,et al. Neoadjuvant chemotherapy for oesophageal cancer: the need for accurate response prediction and evaluation. , 2005, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.
[15] R. Pink,et al. Opportunities and Challenges in Antiparasitic Drug Discovery , 2005, Nature Reviews Drug Discovery.
[16] F. Khuri,et al. Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. , 2004, Seminars in oncology.
[17] A. Bayındırlı,et al. Effect of L-cysteine, kojic acid and 4-hexylresorcinol combination on inhibition of enzymatic browning in Amasya apple juice , 2004 .
[18] T. Beer,et al. Prevention and management of prostate cancer chemotherapy complications. , 2004, The Urologic clinics of North America.
[19] B. Gullberg,et al. Estimation of liver tumor volume using different formulas—An experimental study in rats , 2004, Journal of Cancer Research and Clinical Oncology.
[20] C. Duckett,et al. Dying for NF-kappaB? Control of cell death by transcriptional regulation of the apoptotic machinery. , 2003, Current opinion in cell biology.
[21] P. Zinzani. Complications of cytotoxic chemotherapy in older patients: focus on myelotoxicity in lymphomas. , 2003, Critical reviews in oncology/hematology.
[22] J. Horton. Global anthelmintic chemotherapy programs: learning from history. , 2003, Trends in parasitology.
[23] P. Dennis,et al. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[24] R. Orlowski,et al. NF-kappaB as a therapeutic target in cancer. , 2002, Trends in molecular medicine.
[25] G. Wahl,et al. p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. , 2002, Cancer cell.
[26] M. Leng,et al. Interstrand cross-links of cisplatin induce striking distortions in DNA. , 1999, Journal of inorganic biochemistry.
[27] J. Lokich,et al. Paclitaxel, cisplatin, etoposide combination chemotherapy: a multifractionated bolus dose schedule for non-small cell lung cancer. , 1998, European journal of cancer.
[28] S. Harrison,et al. Structure of an IkappaBalpha/NF-kappaB complex. , 1998, Cell.
[29] L. Kennedy,et al. Assessment and management of chemotherapy-induced mucositis in children. , 1997, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.
[30] C. Scully,et al. Oral complications of cancer therapies: prevention and management. , 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).
[31] R. Hay,et al. Regulation of the DNA binding activity of NF-κB , 1995 .
[32] S. Howell,et al. In vivo modulation of cisplatin cytotoxicity by the cholecystokinin antagonist MK-329 in human pancreatic cancer xenografts. , 1994, Anticancer research.
[33] E. Touboul,et al. Multidisciplinary treatment approach to locally advanced non-inflammatory breast cancer using chemotherapy and radiotherapy with or without surgery. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[34] J. French,et al. Development and validation of a cellular transplant model for leukemia in Fischer rats: a short-term assay for potential anti-leukemic chemicals. , 1989, Leukemia research.
[35] R. Chhabra. NTP Toxicology and Carcinogenesis Studies of 4-Hexylresorcinol (CAS No. 136-77-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies). , 1988, National Toxicology Program technical report series.
[36] K. Achyuthan,et al. Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity. , 1987, The Journal of biological chemistry.
[37] P. Bungay,et al. Activation of transglutaminase at calcium levels consistent with a role for this enzyme as a calcium receptor protein , 1985, Bioscience reports.
[38] R. Gilman,et al. The treatment of Fasciolopsis buski infection in children: a comparison of thiabendazole, mebendazole, levamisole, pyrantel pamoate, hexylresorcinol and tetrachloroethylene. , 1985, Transactions of the Royal Society of Tropical Medicine and Hygiene.